Cargando…

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy

SIMPLE SUMMARY: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is an effective treatment for patients with prostate cancer. However, survival after radioligand therapy differs widely because patients respond differently to treatment but also enter therapy with an individual set of risk factors. We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaal, Sebastian, Huang, Kai, Rogasch, Julian M. M., Jochens, Hans V., De Santis, Maria, Erber, Barbara, Amthauer, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605155/
https://www.ncbi.nlm.nih.gov/pubmed/37894274
http://dx.doi.org/10.3390/cancers15204907
_version_ 1785127005775200256
author Gaal, Sebastian
Huang, Kai
Rogasch, Julian M. M.
Jochens, Hans V.
De Santis, Maria
Erber, Barbara
Amthauer, Holger
author_facet Gaal, Sebastian
Huang, Kai
Rogasch, Julian M. M.
Jochens, Hans V.
De Santis, Maria
Erber, Barbara
Amthauer, Holger
author_sort Gaal, Sebastian
collection PubMed
description SIMPLE SUMMARY: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is an effective treatment for patients with prostate cancer. However, survival after radioligand therapy differs widely because patients respond differently to treatment but also enter therapy with an individual set of risk factors. We retrospectively analyzed the prognostic factors and survival data of 91 patients who were treated in our hospital. We found that patients with more previous lines of chemotherapy, higher levels of the prostate-specific antigen, and a higher “De Ritis ratio” (calculated from two laboratory parameters) lived—on average—for a shorter time after radioligand therapy than patients without these factors. We developed a score to better define patients with different survival outcomes after treatment. Between the highest and lowest risk groups, survival ranged from approximately 5 months to 28 months, respectively. If an independent validation of this score is successful, it could help doctors identify those patients not likely to benefit from radioligand therapy. ABSTRACT: The De Ritis ratio (=aspartate transaminase/alanine transaminase) has shown prognostic value in different cancer types. This is the first such analysis in prostate cancer patients undergoing radioligand therapy (RLT) with [(177)Lu]Lu-PSMA-617. This retrospective monocentric analysis included 91 patients with a median of 3 RLT cycles (range 1–6) and median cumulative activity of 17.3 GBq. Univariable Cox regression regarding overall survival (OS) included age, different types of previous treatment, metastatic patterns and different laboratory parameters before RLT. Based on multivariable Cox regression, a prognostic score was derived. Seventy-two patients (79%) died (median follow-up in survivors: 19.8 months). A higher number of previous chemotherapy lines, the presence of liver metastases, brain metastases, a higher tumor load on PSMA-PET, a higher prostate-specific antigen (PSA) level, lower red blood cell count, lower hemoglobin, higher neutrophil-lymphocyte ratio and higher De Ritis ratio were associated with shorter OS (each p < 0.05). In multivariable Cox, a higher number of chemotherapy lines (range, 0–2; p = 0.036), brain metastases (p < 0.001), higher PSA (p = 0.004) and higher De Ritis ratio before RLT (hazard ratio, 1.27 per unit increase; p = 0.023) remained significant. This prognostic score separated five groups with a significantly different median OS ranging from 4.9 to 28.1 months (log-rank test, p < 0.001). If validated independently, the De Ritis ratio could enhance multifactorial models for OS after RLT.
format Online
Article
Text
id pubmed-10605155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106051552023-10-28 Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy Gaal, Sebastian Huang, Kai Rogasch, Julian M. M. Jochens, Hans V. De Santis, Maria Erber, Barbara Amthauer, Holger Cancers (Basel) Article SIMPLE SUMMARY: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is an effective treatment for patients with prostate cancer. However, survival after radioligand therapy differs widely because patients respond differently to treatment but also enter therapy with an individual set of risk factors. We retrospectively analyzed the prognostic factors and survival data of 91 patients who were treated in our hospital. We found that patients with more previous lines of chemotherapy, higher levels of the prostate-specific antigen, and a higher “De Ritis ratio” (calculated from two laboratory parameters) lived—on average—for a shorter time after radioligand therapy than patients without these factors. We developed a score to better define patients with different survival outcomes after treatment. Between the highest and lowest risk groups, survival ranged from approximately 5 months to 28 months, respectively. If an independent validation of this score is successful, it could help doctors identify those patients not likely to benefit from radioligand therapy. ABSTRACT: The De Ritis ratio (=aspartate transaminase/alanine transaminase) has shown prognostic value in different cancer types. This is the first such analysis in prostate cancer patients undergoing radioligand therapy (RLT) with [(177)Lu]Lu-PSMA-617. This retrospective monocentric analysis included 91 patients with a median of 3 RLT cycles (range 1–6) and median cumulative activity of 17.3 GBq. Univariable Cox regression regarding overall survival (OS) included age, different types of previous treatment, metastatic patterns and different laboratory parameters before RLT. Based on multivariable Cox regression, a prognostic score was derived. Seventy-two patients (79%) died (median follow-up in survivors: 19.8 months). A higher number of previous chemotherapy lines, the presence of liver metastases, brain metastases, a higher tumor load on PSMA-PET, a higher prostate-specific antigen (PSA) level, lower red blood cell count, lower hemoglobin, higher neutrophil-lymphocyte ratio and higher De Ritis ratio were associated with shorter OS (each p < 0.05). In multivariable Cox, a higher number of chemotherapy lines (range, 0–2; p = 0.036), brain metastases (p < 0.001), higher PSA (p = 0.004) and higher De Ritis ratio before RLT (hazard ratio, 1.27 per unit increase; p = 0.023) remained significant. This prognostic score separated five groups with a significantly different median OS ranging from 4.9 to 28.1 months (log-rank test, p < 0.001). If validated independently, the De Ritis ratio could enhance multifactorial models for OS after RLT. MDPI 2023-10-10 /pmc/articles/PMC10605155/ /pubmed/37894274 http://dx.doi.org/10.3390/cancers15204907 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gaal, Sebastian
Huang, Kai
Rogasch, Julian M. M.
Jochens, Hans V.
De Santis, Maria
Erber, Barbara
Amthauer, Holger
Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
title Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
title_full Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
title_fullStr Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
title_full_unstemmed Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
title_short Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
title_sort prognostic value of the de ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [(177)lu]lu-psma-617 radioligand therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605155/
https://www.ncbi.nlm.nih.gov/pubmed/37894274
http://dx.doi.org/10.3390/cancers15204907
work_keys_str_mv AT gaalsebastian prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy
AT huangkai prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy
AT rogaschjulianmm prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy
AT jochenshansv prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy
AT desantismaria prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy
AT erberbarbara prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy
AT amthauerholger prognosticvalueofthederitisratioforoverallsurvivalinpatientswithmetastaticcastrationresistantprostatecancerundergoing177lulupsma617radioligandtherapy